



Maidenhead and Thames Valley Advisers

Presentation and Networking Event

Wednesday, 22 March 2017

Adobe, Market St, Maidenhead, SL6 8AD

15:30 Registration and Coffee/Tea

15:45 Welcome & Introductions

16:00 Company Presentations (1st round)

Bactest



Nalia

16:30 Break & refreshments

16:45 Keynote presentation – Budget, Brexit and Healthcare

17:00 Company Presentations (2nd round)



Jodytrak

propagator

17:30 Hale and Company – Wealth Management & Independent Financial Advice

17:40 Closing remarks

17.45 Meet the companies over networking & refreshments

19:00 Close

Sponsored by:



Supported by:



**MAIDENHEAD
& DISTRICT
CHAMBER OF COMMERCE**

Presentations are provided on a private and confidential basis for information purposes only. MTVA4Life is a trading name of Illiria Limited, registered Office Belmont Place, Belmont road, Maidenhead, Berkshire, SL6 6TB. Registered in England and Wales: No. 07851357, VAT No. 223479408.
Investment in new business carries high risks as well as the possibility of high rewards. It is highly speculative and potential investors should be aware that no established market exists for the trading of share in private companies. Before investing in a project about which information is given, potential investors are strongly advised to take advice from a person authorised by the financial service and markets Act 2000 (FSMA) who specialises in advising on investments of this kind. MTVA4Life cannot advise on the merits or risks of investments and is not authorised to arrange transaction or circulate offer documents under the FSMA. MTVA4Life is an exempt body for the purpose of arranging deals in investments under the statutory instrument 1201 of 2000.

www.mtva4life.com

Company Summaries

Company: Bactest

Prof. Annie Brooking, CEO

Location: Cambridge

Website: www.bactest.com

Clean Tech

The logo for Bactest, featuring the word "Bactest" in a bold, sans-serif font. The "B" is red, and the rest of the letters are black.

Bactest is a Cambridge based company that has three products protected by 10 patents that are both selling. The UK spends 2% of all of the electricity it generates aerating waste water to ensure bacteria are optimal for the process. There is no fast way to measure required aeration so water companies over-aerate to make sure the process does not fail. Shepherd measures the exact aeration required every 60 minutes, can be connected to control systems and via its Cloud based Dashboard sends email alarms for plant anomalies such as toxic shock, and equipment failure and keeps a complete audit of plant behaviour. Shepherd is sold directly and via a growing network of distributors that currently includes China and Brazil. We have recently won a Euro 1.7 million grant for Shepherd trials and further product development.

Speedy Breedy is a portable fast contamination test (around the size of a loaf of bread) for liquid, swabs and small solids that does not require laboratory conditions or qualified staff to run and interpret the test results. Speedy Breedy is a lab-in-a-box whose major markets are health care, and food and beverage. In December 2016 we launched a unique product variant Speedy Breedy Sea Sure for the huge ballast water testing market. Speedy Breedy is sold by a network of 56 distributors We seek £600k. Pre money valuation £3.5 million, £40 per share.

Company: Cambridge Oncometrix

Dr. Maxim Rossmann, PhD, CEO

Location: Suffolk

Website: www.cambridgeoncometrix.com

Diagnostic platform



Cambridge Oncometrix (CamOnx) is developing a simple, non-invasive and cost-effective diagnostic test for prostate cancer based on chemical element composition of seminal and prostatic fluid.

The test is based on the proprietary diagnostic technology that is more accurate than existing tests and can be adapted for primary and secondary care, and also for home use. It permits avoidance of expensive biopsies and prioritization of biopsies where they are truly needed - a benefit, which of strong interest in healthcare providers.

More importantly, CamOnx test will make an affordable regular monitoring and self-monitoring possible - the only way to identify those men in whom indolent disease is in the transition into an aggressive form.

The company conducts a proof-of-concept clinical investigation, which already reached statistically significant results. CamOnx aims to extend the clinical trial to UK and seeks funding for the regulatory approvals and development of a home test.

Company: Nalia Systems

Marcus Harrison, CEO

Location: London

Website: www.naliasystems.com

Point of care diagnostic platform



Nalia was founded to develop and commercialise a unique patented technology that enables an array of multiple diagnostic disease markers in a single 10 minute test. Each Nalia array will replace tens of existing individual biological assays into a single test, for use in clinical research and diagnosis and monitoring of disease. Furthermore, the panel of biomarkers can be combined with clinically validated algorithms to improve the diagnosis of complex diseases without increasing healthcare costs.

Initially Nalia are developing panels of biomarkers into industry standard multiwall format that will be used to identify biological signatures of complex diseases. Ultimately the technology will be transferred into a simple-to-use disposable cartridge and instrument to enable clinicians to diagnose complex diseases within 10 minutes without the delay in sending blood samples to centralized laboratories and waiting several days for results to be returned.

Nalia are looking to raise a £500k during 2017.

Company: Fourth State Medicine

Dr. Thomas Frame, CEO

Location: Fernhurst

Website: www.fourthstatemedicine.co.uk

Medical Technologies



Fourth State Medicine Ltd has developed a revolutionary platform technology for use in a number of diverse and high value markets, from cosmetic partners using it to reduce wrinkles, NHS partners treating diabetic ulcers and other long term applications in veterinary and food sectors.

Using innovative techniques inspired from the cutting edge of space technology, the device eradicates resistant bacteria including MRSA and improves skin condition. The Company has just entered the cosmetic sector with sales of its first product, and is looking to raise capital to grow its UK order book and address interest from the US and Europe.

Company: Inova/Bodytrak
Leon Marsh, Founder and CEO

Location: London

Website: www.bodytrak.co

Medical Technologies



Bodytrak®

Bodytrak® is the next generation in wearable technology. With the steady decline of sales in wrist-based wearables, the ear is the new location set to transform the industry with a growth of over 2500% annually. With a much better signal-to-noise ratio than the wrist, significant improvements can be made to reliability and accuracy. Bodytrak is the first solution to implement precision physiology monitoring into a compact earpiece providing automated real-time data and powerful cloud-based analytics, utilising both machine learning and intelligent algorithms to give unrivalled real-time insights to enable marginal gains and greater success as well as early intervention to reduce risk and associated insurance premiums.

It is the only device to be able to measure core body temperature unobtrusively and as accurately as medical devices. This provides significant advances in the monitoring of elite athletes, industrial workforces, fire fighters, soldiers and patients. Bodytrak also measures heart rate and motion and provides two-way communications, which means Bodytrak can determine, for example, when someone has fallen and how urgent a recovery is, whilst enabling a response team to communicate with the user directly.

The largely enterprise focused model will be monetised through a subscription PaaS model via direct and partner channels.

Company: Propagator

Chris Robson, CEO

Location: London

Website: www.propagatorgroup.com

Health Management Platform

propagator

Propagator is a profitable technology provider, with existing revenues, (£1.5m in 15-16), existing software products and existing customers (Harper Collins, Penguin Random House, Informa, Bloomsbury and the NHS). Propagator conceived and developed Squeezy, the market leading continence app, working with the NHS and designed the world's first contactless sleep tracker for ResMed.

Propagator is now developing a "Living with a chronic condition" digital platform to improve the lives of the 15m UK patients with long-term conditions, such as back pain, arthritis, cancer, hypertension and depression, and save costs for healthcare providers. It is a single, cloud based technology platform, which is app and web based, and can be configured for any provider and condition.

We are launching Living with Rheumatoid Arthritis with NHS RUH in Bath in April, are developing Living with Back Pain with Chelsea and Westminster Hospital and developing Living with Pelvic Health with some private sector companies.

MTVA4Life event is kindly sponsored by:



Hale & Company LLP is a long standing firm of Chartered Accountants and Chartered tax Advisers based in the Thames Valley providing a range of accounting, and specialist tax services. We have a highly experienced team, with our strengths focusing on start-ups, outsourced finance services utilising some of the latest cloud accounting technologies and private client work where we have a passion for client service. Our client base is largely made up of owner managed businesses and inward investing companies who value expert advice and professional service delivery. For further information please see our website

www.haleandco.co.uk

MTVA4Life is grateful for the support of



**MAIDENHEAD
& DISTRICT
CHAMBER OF COMMERCE**



Catering kindly provided by:



Presentations are provided on a private and confidential basis for information purposes only.

MTVA4Life is a trading name of Illiria Limited, registered Office Belmont Place, Belmont road, Maidenhead, Berkshire, SL6 6TB. Registered in England and Wales: No. 07851357, VAT No. 223479408.

Investment in new business carries high risks as well as the possibility of high rewards. It is highly speculative and potential investors should be aware that no established market exists for the trading of share in private companies. Before investing in a project about which information is given, potential investors are strongly advised to take advice from a person authorised by the financial service and markets Act 2000 (FSMA) who specialises in advising on investments of this kind. MTVA4Life cannot advise on the merits or risks of investments and is not authorised to arrange transaction or circulate offer documents under the FSMA. MTVA4Life is an exempt body for the purpose of arranging deals in investments under the statutory instrument 1201 of 2000. www.mtva4life.com

NOTES